Acrivon Therapeutics, Inc.
ACRV
$1.33
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.32M | 25.26M | 25.21M | 24.46M | 24.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.41M | 93.19M | 89.20M | 85.30M | 76.30M |
| Operating Income | -94.41M | -93.19M | -89.20M | -85.30M | -76.30M |
| Income Before Tax | -85.96M | -83.75M | -80.56M | -76.98M | -69.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -85.96 | -83.75 | -80.56 | -76.98 | -69.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.96M | -83.75M | -80.56M | -76.98M | -69.00M |
| EBIT | -94.41M | -93.19M | -89.20M | -85.30M | -76.30M |
| EBITDA | -93.21M | -92.10M | -88.19M | -84.45M | -75.56M |
| EPS Basic | -2.25 | -2.22 | -2.44 | -2.70 | -2.77 |
| Normalized Basic EPS | -1.42 | -1.40 | -1.54 | -1.71 | -1.75 |
| EPS Diluted | -2.25 | -2.22 | -2.44 | -2.70 | -2.77 |
| Normalized Diluted EPS | -1.42 | -1.40 | -1.54 | -1.71 | -1.75 |
| Average Basic Shares Outstanding | 153.16M | 150.83M | 135.07M | 119.16M | 103.14M |
| Average Diluted Shares Outstanding | 153.16M | 150.83M | 135.07M | 119.16M | 103.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |